IC
VRTX icon

Investment Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Investment Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,000
Closed -$516K – 67
2016
Q2 		$516K Buy
+6,000
New +$518K 0.42% 52

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Investment Counsel's VRTX Position: Q3 2016 in Review

Investment Counsel sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 6,000 shares — an estimated $516K sold.

Investment Counsel first reported a position in VRTX in Q2 2016 and held it in 1 quarter. The position peaked at $516K in Q2 2016. 489 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

  • Investment Counsel reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Investment Counsel sold 6,000 Vertex Pharmaceuticals shares in Q3 2016, an estimated $516K.
  • Investment Counsel first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Investment Counsel's Vertex Pharmaceuticals position peaked at $516K in Q2 2016.
  • 489 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Investment Counsel's 13F filing for Q3 2016, filed 10 Nov 2016.